Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Osteogenesis imperfecta (OI) is a heterogeneous connective tissue disorder characterized by brittle bones. Four clinical subtypes are recognized, including a mild (type I), a lethal (type II), a ...

Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Parents, have you ever heard of osteogenesis imperfecta? This is a disease that often attacks bones. This disorder can attack children from birth. Osteogenesis imperfecta also has many types with ...

Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone ...